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Highlights
• We developed a stochastic tumour-immune dynamical model concern-
ing pulsed treatment.
• Conditions for the three phases of cancer immunoediting are provided.
• The results reveal that comprehensive therapy or noise can dominate
evolution of tumours.
• Biological implications for cancer treatment are presented.
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Abstract
Periodical applications of immunotherapy and chemotherapy play signif-
icant roles in cancer treatment and studies have shown that the evolution
of tumour cells is subject to random events. In order to capture the ef-
fects of such noise we developed a stochastic tumour-immune dynamical
model with pulsed treatment to describe combinations of immunotherapy
with chemotherapy. By using theorems of the impulsive stochastic dynami-
cal equation, the tumour free solution and the global positive solution of the
proposed system were investigated. We then show that the expectations of
the solutions are bounded. Furthermore, threshold conditions for extinction,
non-persistence in the mean, weak persistence and stochastic persistence of
tumour cells are provided. The results reveal that comprehensive therapy or
noise can dominate the evolution of tumours. Finally, biological implications
are addressed and a conclusion is presented.
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1. Introduction
The malignant tumours of cancer result from the abnormal proliferation
of cells. Cancer remains a worldwide aggressive disease and its treatment
is still fraught with challenges. Traditional methods of treatment usually
include surgery, radiotherapy and chemotherapy. However, these methods
either cannot completely clear cancer cells or cause many negative side ef-
fects in the patients. To overcome these drawbacks, new treatments based
on immunotherapy, intended to stimulate a strong immune response to its
target tumours, has been used to cure cancer [1, 2]. Pre-clinical data and
phased clinical studies have emphasized that immunotherapy may not only
clear the tumour cells, but can also enhance the efficacy of chemotherapy or
radiotherapy [3-5].
Mathematical models have been used to study the interactions between
tumor cells and immune cells [6-9]. In 1994, Kuznetsov constructed a novel
tumour-immune dynamical model and the results showed how the tumour
growth stimulated the immune response and how dormancy in tumours oc-
curs [10]. The simple model consisted of two ordinary differential equations,
where the effector cells (such as TIL or NK cells) act as role of predator,
while the tumour cells play the role of the prey. Many phenomena were
studied, such as immunostimulation of tumour growth, sneaking through of
the tumour, and formation of a tumour dormant state. Later, Kirschner and
Panetta extended this tumour-immune model by introducing immunother-
apy [11]. The continuous injections of interleukin-2 (IL-2) were investigated
and the conditions for short-term oscillations for tumour cells and for long-
term tumour relapse were provided. Wei and Yang later studied pulsed
tumour-immune models with immunotherapy and chemotherapy applied pe-
riodically [12, 13]. The conditions for the tumour free periodic solution were
obtained and it was confirmed that Adoptive Cellular Immunotherapy (ACI)
applied more frequently than inputs of IL-2 were a better way to cure cancer.
Moreover, Tang and co-authors developed a series of tumour-immune mod-
els incorporating comprehensive therapy [14-16]. Surgery together with ACI
and IL-2 were implemented once tumour cells or effector cells reached critical
values. Periodic solutions and bifurcations were studied and the biological
significance of the results for cancer treatment was also addressed.
A very important assumption in the above studies is that the growth
of both tumour cells and effector cells follow deterministic laws. But most
natural phenomena are influenced by stochastic processes rather than only
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by strictly deterministic laws [17], and the tumour cells are no exception
[18]. For instance, changes in the environment can lead to changes in the
enzymatic activity of proteins, which will affect the growth of tumour cells
[19]. Thus, it is more reasonable to describe the growth of tumour cells by
using stochastic differential equations. Li and Cheng considered a stochastic
tumour growth model and obtained conditions for extinction and persistence
of tumour cells [19], and Caravagna investigated the effects of stochastic
oscillations on tumour suppression [20]. Wang and co-authors studied how
environmental fluctuations affected the dynamics of tumour cells [21].
However, there are few stochastic tumour-immune models with compre-
hensive therapy. In experimental and clinical studies, immunotherapeutic
drugs and chemotherapy drugs are often injected at fixed periods to cure
cancer [22, 23]. Such pulsed treatments, which can be described by impul-
sive differential equations [24, 25], have proved to be essential for governing
whether the comprehensive treatment was successful or not [9]. Therefore, it
is necessary to consider both environmental fluctuations and pulsed therapy
in a tumour-immune model, and further to address how random noise and key
factors (including the period of therapy, a clear rate representing the inten-
sity of treatment and the growth rate stimulated by immunotherapy) affect
the outcomes of the treatment. Thereby, we propose a stochastic tumour-
immune model with pulsed comprehensive therapy to solve these problems.
And such stochastic systems with pulsed control have been widely applied
in many fields and sciences, such as in predator-prey systems [26-28], virus
dynamical systems [29], and epidemic dynamical systems [30].
The structure of this paper is divided into the following sections: Some
important definitions and lemmas about the impulsive stochastic dynamical
equation are introduced in section 2. In section 3, the existence and unique-
ness of a global positive solution for system (2.2) will be studied. In section
4, the conditions for the extinction and persistence of the tumour cells and
effector cells are provided. Numerical investigations are carried out in sec-
tion 5. In section 6, biological implications about the cancer treatment are
addressed, followed by concluding remarks.
2. Mathematical Model
2.1. Model formation
Let x(t) be the tumour cells and y(t) be the effector cells include cytotoxic
T-cells, macrophages, and natural killer cells that act on the tumour cells.
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Assume that the tumour cell and effector cell play the role of the prey and
predator, then the tumour-immune dynamical model proposed by Kuznetsov
can be described by [10],
dx(t)
dt
= rx(t)(1− ηx(t))− ax(t)y(t),
dy(t)
dt
=
bx(t)y(t)
1 + wx(t)
− cx(t)y(t)− dy(t),
(2.1)
where r is the intrinsic growth rate of tumour cells, 1/η is the carrying
capacity of tumour cells, a is the rate at which the effector cells bind to the
tumour cells, c is the inactivation rate of effector cells, d is the death rate
of effector cells, b denotes the maximum immune response rate due to the
presence of tumour cells and w is the steepness of the immune response.
Based on system (2.1), we propose a stochastic tumour-immune dynam-
ical model concerning pulsed treatment, so the extended model (2.1) is

dx(t) = [rx(t)(1− ηx(t))− ax(t)y(t)]dt+ δ1x(t)dB1(t),
dy(t) =
[
bx(t)y(t)
1+wx(t)
− cx(t)y(t)− dy(t)
]
dt+ δ2y(t)dB2(t),
 t 6= nT,
x(nT+) = (1− a(nT ))x(nT ),
y(nT+) = (1 + b(nT ))y(nT ),
}
t = nT,
(2.2)
where δ21 and δ
2
2 are the intensity of the noise on the tumour cells and effector
cells, respectively, andB1(t) andB2(t) denote independent Brownian motions
with Bi(0) = 0. T is the period for the pulsed therapy, n is a positive integer.
In reality, the chemotherapy drug kills both the tumour cells and the effector
cells, but although the killing rates for them will differ, we do not take this
into account. a(nT ) is the killing rate of the chemotherapy, b(nT ) denotes the
net growth rate of the effector cells stimulated by immunotherapy. b− c > 0
for biological significance.
2.2. Preliminaries
In the rest of the paper, let (Ω,F , {Ft}t≥0,P) be a complete probabil-
ity space with a filtration {Ft}t≥0 which satisfies the usual conditions. We
assume that the independent Brownian motion Bi(t) is defined on this prob-
ability space. If the number of factors of a product is zero then we assume
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that this produc equals unity. Now we introduce some useful definitions of
the paper.
Definition 1. ([31]) X(t) = (x(t), y(t))T , t ∈ R+ = [0,+∞), is called a
solution of ISDE (2.2) with initial condition X(0) = X0 ≥ 0 if the following
holds:
(1) X(t) is absolutely continuous on (0, T ] and (nT, (n+ 1)T ];
(2) for any nT , we haveX(nT−) = limt→nT− X(t) andX(nT+) = limt→nT+ X(t)
and X(nT ) = X(nT−);
(3) X(t) obeys system (2.2) for every t ∈ R+ − nT and at pulsed point nT
satisfies the pulse condition.
Definition 2. ([32, 33]) Let X(t) = (x(t), y(t))T be a solution of ISDE (2.2):
(1) x(t) is called extinctive if limt→+∞ x(t) = 0;
(2) x(t) is called non-persistent in the mean if limt→+∞ 1t
∫ t
0
x(s)ds = 0;
(3) x(t) is called weakly persistent in the mean if limt→+∞ sup 1t
∫ t
0
x(s)ds > 0;
(4) if for each ε ∈ (0, 1), there exists β > 0 and δ > 0 so that
lim inf
t→+∞
P{x(t) ≥ β} ≥ 1− ε, lim inf
t→+∞
P{x(t) ≤ δ} ≥ 1− ε,
then x(t) is called stochastically persistent.
Remark 1. Biologically, these definitions are very important to explain three
phases of cancer immunoediting, i.e., the extinction, weakly persistence and
stochastic persistence correspond to the phase of elimination, the phase of
equilibrium and the phase of escape, respectively. Besides, extinction means
non-persistence in the mean, but the reverse is not true.
Definition 3. Suppose that X1(t), X2(t) are any two solutions of ISDE (2.2)
with X1(0) > 0, X2(0) > 0, if limt→+∞ | x1(t) − x2(t) |= 0 and limt→+∞ |
y1(t)− y2(t) |= 0, then ISDE (2.2) is called globally attractive.
Lemma 1 [34]. Let f(t) ∈ C(Ω×R+, R+ − 0),
(1) if there are constants ζ0, t1 and ζ ≥ 0 such that f(t) satisfies
ln f(t) ≤ ζt− ζ0
∫ t
0
f(s)ds+
n∑
i=1
βiBi(t)
for any t ≥ t1, βi is also a constant, then we have
lim
t→+∞
sup
1
t
∫ t
0
f(s)ds ≤ ζ
ζ0
.
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(2) if there are constants ζ0, t1 and ζ ≥ 0 such that f(t) satisfies
ln f(t) ≥ ζt− ζ0
∫ t
0
f(s)ds+
n∑
i=1
βiBi(t)
for any t ≥ t1, then we have
lim
t→+∞
sup
1
t
∫ t
0
f(s)ds ≥ ζ
ζ0
.
3. Global positive solution
3.1. Tumour free solution
We first consider a special case. Suppose that chemotherapy and im-
munotherapy are very effective and that the tumour cells can then be erad-
icated by effector cells in a short time. Let x(t) = 0, then system (2.2) can
be reduced to the following simple subsystem:{
dy(t) = −dy(t)dt+ δ2y(t)dB2(t), t 6= nT,
y(nT+) = (1 + b(nT ))y(nT ), t = nT.
(3.1)
We show that system (3.1) has a global positive solution based on refer-
ence [27].
Theorem 1. System (3.1) has a unique global positive solution y(t) with
initial value y(0+) = y(0) which can be expressed by
y(t) =
∏
0<nT<t
(1 + b(nT ))y(0) exp[(−d− 0.5δ22)t+ δ2B2(t)]. (3.2)
Proof. Let V (t) = ln y(t) for any t ∈ (nT, (n+ 1)T ]. By using Itoˆ’s formula
we obtain
d ln y(t) = (−d− 0.5δ22)dt+ δ2dB2(t).
Integrating the above equation from nT to t yields
ln y(t)− ln y(nT ) = (−d− 0.5δ22)(t− nT ) + δ2(B2(t)−B2(nT )).
At time t = nT+, immunotherapy is applied once and then
y(t) = (1 + b(nT ))y(nT ) exp[(−d− 0.5δ22)(t− nT ) + δ2(B2(t)−B2(nT ))].
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It follows by induction that we get the global positive solution y(t) of system
(3.1)
y(t) =
∏
0<nT<t
(1 + b(nT ))y(0) exp[(−d− 0.5δ22)t+ δ2B2(t)].
This completes the proof.
3.2. Global positive solution of system (2.2)
Now, we need to show that the solutions of system (2.2) should be non-
negative, which are very useful for the rest of the paper.
Theorem 2. System (2.2) has a global unique positive solution (x(t), y(t))
for any initial point (x(0), y(0)) ∈ R2+ = {(x(t), y(t))|x(t) > 0, y(t) > 0} and
the solution (x(t), y(t)) will remain in R2+.
Proof. To show the existence of solutions of system (2.2), we focus on the
following auxiliary SDE without pulsed effects:
dx1(t) = x1[r − rη
∏
0<nT<t(1− a(nT ))x1 − a
∏
0<nT<t(1 + b(nT ))y1]dt
+δ1x1dB1(t),
dy1(t) = y1
[
b
∏
0<nT<t(1−a(nT ))x1
1+w
∏
0<nT<t(1−a(nT ))x1 − c
∏
0<nT<t(1− a(nT ))x1 − d
]
dt
+δ2y1dB2(t),
(3.3)
where the initial point is defined as (x1(0), y1(0)) = (x(0), y(0)). Note that
Liu and Wang showed that system (3.3) has a unique global positive solu-
tion (x1(t), y1(t)) by using theories of SDEs [27]. Denote by (x(t), y(t)) =
(
∏
0<nT<t(1− a(nT ))x1(t),
∏
0<nT<t(1 + b(nT ))y1(t)) with (x(0), y(0)) as ini-
tial point, it follows from the absolute continuity of (x1(t), y1(t)) that (x(t), y(t))
is also absolutely continuous for any t ∈ (nT, (n + 1)T ] ⊂ [0,+∞), n ∈ N .
For t 6= nT , taking the derivatives of (x(t), y(t)) and combining model (3.3)
yields
dx(t) =
∏
0<nT<t(1− a(nT ))dx1(t)
=
∏
0<nT<t(1− a(nT ))x1[r − rη
∏
0<nT<t(1− a(nT ))x1
−a∏0<nT<t(1 + b(nT ))y1]dt+ δ1x1dB1(t)
= [rx(t)(1− ηx(t))− ax(t)y(t)]dt+ δ1x(t)dB1(t),
dy(t) =
∏
0<nT<t(1 + b(nT ))dy1(t)
= y(t)[
b
∏
0<nT<t(1−a(nT ))x1
1+w
∏
0<nT<t(1−a(nT ))x1 − c
∏
0<nT<t(1− a(nT ))x1 − d]dt
+δ2y1dB2(t)
= [ bx(t)y(t)
1+wx(t)
− cx(t)y(t)− dy(t)]dt+ δ2y(t)dB2(t).
8
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Moreover, for any t = nT , we obtain
x(nT+) = limt→nT+
∏
0<iT<t(1− a(iT ))x1(t) =
∏
0<iT≤nT (1− a(iT ))x1(nT ),
y(nT+) = limt→nT+
∏
0<iT<t(1 + b(iT ))y1(t) =
∏
0<iT≤nT (1 + b(iT ))y1(nT ),
(3.4)
besides,
x(nT ) =
∏
0<iT<t(1− a(iT ))x1(nT ),
y(nT ) =
∏
0<iT<t(1 + b(iT ))y1(nT ),
(3.5)
From (3.4) and (3.5), we get
x(nT+) = (1− a(nT )x(nT ), y(nT+) = (1 + b(nT )y(nT ),
Therefore, system (2.2) has a global unique positive solution which is defined
as (x(t), y(t)) = (
∏
0<nT<t(1 − a(nT ))x1(t),
∏
0<nT<t(1 + b(nT ))y1(t)). This
completes the proof.
Theorem 3. If rη − b+ c > 0, then the solution of system (2.2) is globally
attractive.
Proof. Without loss of generality, we assume that (x1(t), y1(t)) and (x2(t), y2(t))
be any two solutions of system (2.2) with initial conditions x(0) > 0, y(0) > 0.
To show the global attractivity of the solution, we resort to constructing a
Lyapunov function which is defined by the following equation:
V (t) =| lnx1(t)− lnx2(t) | + | ln y1(t)− ln y2(t) |,
where t > 0 and t 6= nT . On the one hand, we calculate the upper right
derivative d+V (t) of V (t) and then make use of Itoˆ’s formula along the solu-
tions of system (2.2),
d+V (t) = sign(x1(t)− x2(t))d(lnx1(t)− lnx2(t))
+sign(y1(t)− y2(t))d(ln y1(t)− ln y2(t))
= sign(x1(t)− x2(t))(−rη(x1(t)− x2(t))− a(y1(t)− y2(t)))dt
+sign(y1(t)− y2(t))
(
b(x1(t)−x2(t))
(1+wx1(t))(1+wx2(t))
− c(x1(t)− x2(t))
)
dt
≤ [−(rη − b+ c) | x1(t)− x2(t) | −a | y1(t)− y2(t) |]dt
≤ −ρ(| x1(t)− x2(t) | + | y1(t)− y2(t) |)dt .= −ρV(t)dt,
(3.6)
where ρ = min{rη − b+ c, a}. On the other hand, for t = nT we obtain
V (nT+) = | lnx1(nT+)− lnx2(nT+) | + | ln y1(nT+)− ln y2(nT+) |
= | ln(1− a(nT ))x1(nT )− ln(1− a(nT ))x2(nT ) |
+ | ln(1 + b(nT ))y1(nT )− ln(1 + b(nT ))y2(nT ) |
= | lnx1(nT )− lnx2(nT ) | + | ln y1(nT )− ln y2(nT ) |= V (nT ).
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Integrating equation (3.6) from 0 to t and taking expectation yields
V (t) ≤ V (0)− ρ
∫ t
0
V(s)ds.
Thus,
V (t) + ρ
∫ t
0
V(s)ds ≤ V (0) <∞.
Moreover, V (t) > 0 always holds which leads to limt→+∞V(t) = 0. In other
words,
lim
t→∞
| x1(t)− x2(t) |= 0 and lim
t→∞
| y1(t)− y2(t) |= 0.
This completes the proof.
Theorem 4. For 0 ≤ s < t, if ∏s≤nT<t(1 + b(nT )) ≤ B (B > 0) and
1− d ≤ 0, then any solution X(t) = (x(t), y(t)) of system (2.2) satisfies the
following inequality:
lim
t→∞
E | X(t) |≤ AB,
where A = (b−c)(r+1)
2
4rη
.
Proof. We denote V1(t) = c1x(t)+c2y(t), here c1 = b−c > 0 and c2 = a > 0.
For any t ∈ ((n− 1)T, nT ], it follows from the Itoˆ’s formula for system (2.2)
that we obtain
dV1(t) = c1dx(t) + c2dy(t) = LV (t)dt+ c1δ1x(t)dB1(t) + c2δ2y(t)dB2(t),
with
LV (t) = c1[rx(t)(1−ηx(t))−ax(t)y(t)]+c2
[
bx(t)y(t)
1 + wx(t)
− cx(t)y(t)− dy(t)
]
.
Furthermore, we consider another Lyapunov function V2(t) = e
tV1(t) and the
application of Itoˆ’s formula leads to
dV2(t) = e
tV1(t)dt+ e
tdV1(t)
= etV1(t)dt+ e
t{LV (t)dt+ c1δ1x(t)dB1(t) + c2δ2y(t)dB2(t)}.
Integrating the above equation from (n − 1)T to t and then calculating the
corresponding expectations yields
EetV1(t) = e
(n−1)TV1((n− 1)T ) + E
∫ t
(n−1)T e
s[V1(s) + LV (s)]ds. (3.7)
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Note that
LV + V1 = c1[rx(1− ηx)− axy] + c2
[
bxy
1+wx
− cxy − dy]+ c1x+ c2y
≤ c1(rx− rηx2 + x) + (c2(b− c)− c1a)xy + c2(1− d)y
≤ c1 (r+1)24rη = (b−c)(r+1)
2
4rη
.
= A.
(3.8)
From equations (3.7) and (3.8) we obtain
etEV1(t) ≤ e(n−1)T (V1((n− 1)T )− A) + etA. (3.9)
Using Itoˆ’s formula for (3.9) leads to
dEV1(t) ≤ (A− EV1(t))dt. (3.10)
When t = nT ,
EV1(nT
+) = c1E(x(nT
+)) + c2E(y(nT
+))
= c1(1− a(nT ))E(x(nT )) + c2(1 + b(nT ))E(y(nT ))
≤ (1 + b(nT ))(c1E(x(nT )) + c2E(y(nT )))
= (1 + b(nT ))EV1(nT ).
(3.11)
Equations (3.10) and (3.11) can be rewritten as{
dEV1(t) ≤ (A− EV1(t))dt, t 6= nT,
EV1(nT
+) ≤ (1 + b(nT ))EV1(nT ), t = nT. (3.12)
To show the boundedness of system (3.12), we need to consider the fol-
lowing new system:{
dz(t) = (A− z(t))dt, t 6= nT,
z(nT+) = (1 + b(nT ))z(nT ), t = nT.
(3.13)
The unique solution of system (3.13) is given by
z(t) = z(0)m(t, 0) + A
∫ t
0
m(t, s)ds,
wherem(t, s) =
∏
s≤nT<t(1+b(nT )) exp(−(t−s)). Then we have limt→+∞ z(t) =
AB. It follows from comparison theorems of impulsive differential equations
[24, 25] that we obtain
lim
t→+∞
EV1(t) ≤ lim
t→+∞
z(t) = AB.
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This completes the proof.
Remark 2. Theorem 4 shows that the solutions of system (2.2) have upper
bound in terms of expectations under certain conditions. Biologically, if
pulsed perturbations are bounded or follow after finite pulse immunotherapy,
then the tumour cells will be controlled and will not grow indefinitely.
4. Extinction and persistence
Since we have incorporated stochastic effects into model (2.2), we want to
explore the conditions for the extinction and persistence of the tumour cells
and the effector cells. To show these, we first need to give the following results
by using Itoˆ’s formula. Defining a Lyapunov function V (t) = ln x1(t) and
noting that x(t) =
∏
0<nT<t(1−a(nT ))x1(t), y(t) =
∏
0<nT<t(1+b(nT ))y1(t),
then applying Itoˆ’s formula to the first equation of system (3.3),
d lnx1(t) = [r − rη
∏
0<nT<t(1− a(nT ))x1 − a
∏
0<nT<t(1 + b(nT ))y1
−1
2
δ21]dt+ δ1dB1(t)
= [r − rηx(t)− ay(t)− 1
2
δ21]dt+ δ1dB1(t),
(4.1)
integrating the above equation from 0 to t yields
lnx1(t)− lnx1(0) =
(
r − 1
2
δ21
)
t− rη ∫ t
0
x(s)ds− a ∫ t
0
y(s)ds+M1(t),
(4.2)
where Mi(t) =
∫ t
0
δidBi(t)(i = 1, 2). Taking the pulsed effects of system (2.2)
into equation (4.2) yields∑
0<nT<t ln(1− a(nT )) + ln x1(t)− lnx1(0)
=
∑
0<nT<t ln(1− a(nT )) +
(
r − 1
2
δ21
)
t− rη ∫ t
0
x(s)ds− a ∫ t
0
y(s)ds+M1(t).
(4.3)
Simplification of equation (4.3) yields following lemma.
Lemma 2. For system (2.2) the tumour x(t) satisfies
ln x(t)
x(0)
=
∑
0<nT<t ln(1− a(nT )) +
(
r − 1
2
δ21
)
t− rη ∫ t
0
x(s)ds
−a ∫ t
0
y(s)ds+M1(t).
(4.4)
By applying the same methods we obtain
Lemma 3. For system (2.2) the effector cell y(t) satisfies
ln y(t)
y(0)
=
∑
0<nT<t ln(1 + b(nT ))−
(
d+ 1
2
δ22
)
t− c ∫ t
0
x(s)ds
+b
∫ t
0
x(s)
1+wx(s)
ds+M2(t).
(4.5)
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Theorem 5. (1) If limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+r < 1
2
δ21, then the tumour
cells become extinct.
(2) If limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ r = 1
2
δ21, then the tumour cells are
non-persistent in the mean.
(3) If
lim
t→+∞
sup
∑
0<nT<t ln(1− a(nT ))
t
+ r >
1
2
δ21
and
lim
t→+∞
sup
∑
0<nT<t ln(1 + b(nT ))
t
< d+
1
2
δ22,
then the tumour cells become weakly persistent in the mean.
Proof. (1) It follows from (4.4) that we have
1
t
ln x(t)
x(0)
=
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)− rη ∫ t0 x(s)ds
t
−a
∫ t
0 y(s)ds
t
+ M1(t)
t
.
(4.6)
Note that < Mi(t),Mi(t) >=
∫ t
0
δ2i ds, because of the strong law of large
numbers for local martingales we obtain
limt→+∞
Mi(t)
t
= 0. (4.7)
Taking the superior limit of (4.6) gives
limt→+∞ sup
lnx(t)
t
≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ r − 1
2
δ21
−rηx∗(t)− ay∗(t) < 0,
where x∗(t) = limt→+∞ inf 1t
∫ t
0
x(s)ds and y∗(t) = limt→+∞ inf 1t
∫ t
0
y(s)ds. It
indicates that limt→+∞ x(t) = 0, thereby the tumour cells becomes extinct.
(2) For any fixed ε > 0, there exists a constant t1 so that the following
inequalities hold true for all t ≥ t1:∑
0<nT<t ln(1−a(nT ))
t
≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ ε
2
, M1(t)
t
≤ ε
2
,
combining with (4.6) yields
1
t
ln x(t)
x(0)
=
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)− rη ∫ t0 x(s)ds
t
−a
∫ t
0 y(s)ds
t
+ M1(t)
t
≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)
−rη 1
t
∫ t
0
x(s)ds+ ε.
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When ε is small enough, owing to Lemma 1 we have
limt→+∞ sup 1t
∫ t
0
x(s)ds ≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+(r− 12 δ21)
rη
= 0. (4.8)
Notice that x(t) ≥ 0 always holds and it implies that limt→+∞ sup 1t
∫ t
0
x(s)ds ≥
0. Therefore, limt→+∞ sup 1t
∫ t
0
x(s)ds = 0 and thus the tumour cells are non-
persistent in the mean.
(3) Assume that limt→+∞ sup
x(t)
t
< 0, by calculating the superior limit of
(4.6) yields
rηx∗(t) + ay∗(t) ≥ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+r − 1
2
δ21 − limt→+∞ sup lnx(t)t > 0,
where x∗(t) = limt→+∞ sup 1t
∫ t
0
x(s)ds and y∗(t) = limt→+∞ sup 1t
∫ t
0
y(s)ds.
It implies x∗(t) > 0. Otherwise, for any τ ∈ {x∗(t, τ) = 0}, we obtain
y∗(t, τ) > 0. However, it follows from the superior limit of (4.5) and note
that x∗(t, τ) = 0 that one obtains
limt→+∞ sup
ln y(t,τ)
t
≤ limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22) < 0,
which means that y∗(t, τ) = 0, which contradicts y∗(t, τ) > 0. Therefore,
limt→+∞ sup 1t
∫ t
0
x(t)dt > 0. Thereby the tumour cells become weakly per-
sistent in the mean. This completes the proof.
Theorem 6. (1) If
limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ r < 1
2
δ21,
limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
< d+ 1
2
δ22,
then the effector cells become extinct.
(2) If limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ r = 1
2
δ21, then the effector cells are
non-persistent in the mean.
(3) If
limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)
−
(
b−c
rη
limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
))
> 0,
then the effector cells become weakly persistent in the mean.
Proof. (1) It follows from (4.5) that we have
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1
t
ln y(t)
y(0)
=
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)− c1
t
∫ t
0
x(s)ds
+b1
t
∫ t
0
x(s)
1+wx(s)
ds+ M2(t)
t
.
(4.9)
Taking the superior limit of (4.9) gives
limt→+∞ sup
ln y(t)
t
≤ limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)
+(b− c)x∗(t),
by (4.8) we have x∗(t) < 0, that is to say,
lim
t→+∞
sup
ln y(t)
t
≤ 0.
Therefore, we have limt→+∞ y(t) = 0, which indicates that the effector cells
become extinct.
(2) For any fixed ε > 0, there exists a t2 such that for all t ≥ t2 we obtain:∑
0<nT<t ln(1−a(nT ))
t
≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ ε
2
, M1(t)
t
≤ ε
2
,
combining with (4.6) yields
a1
t
∫ t
0
y(s)ds = −1
t
ln x(t)
x(0)
+
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)− rη ∫ t0 x(s)ds
t
+M1(t)
t
≤ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)
+ ε.
When ε is small enough, taking the superior limit yields
limt→+∞ sup 1t
∫ t
0
y(s)ds ≤ 0. (4.10)
Therefore, limt→+∞ sup 1t
∫ t
0
y(s)ds = 0 and thus the effector cells are non-
persistent in the mean.
(3) From (4.9) we have
1
t
ln y(t)
y(0)
≥
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)− (b+ c)1
t
∫ t
0
x(s)ds+ M2(t)
t
,
(4.11)
then (4.6) and (4.11) and taking the superior limit, there exists a t3 > 0 such
that
ln y(t)
t
≥ limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)
+ limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)
−(rη − b+ c)x∗(t)− ay∗(t),
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and it follows from (4.8) that we obtain
ay∗(t) ≥ limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)
−
(
b−c
rη
limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
))
> 0.
which means that y∗(t) = limt→+∞ sup 1t
∫ t
0
y(s)ds > 0. This completes the
proof.
During the whole stages of treatment, the times of pulsed therapy are
limited. So the following assumption is reasonable.
Assumption 1. There exist four positive constants m1, m2 ,M1 and M2 such
that m1 ≤
∏
0<nT<t(1− a(nT )) ≤M1 and m2 ≤
∏
0<nT<t(1 + b(nT )) ≤M2.
Theorem 7. Based on assumption 1, if τ = mint≥0[r− 12δ21−aM2] > 0, then
the tumour cells are stochastically permanent.
Proof. We first need to prove that there exists two constants β > 0 and
% > 0 such that lim inft→+∞ P{x(t) ≥ β} ≥ 1 − ε and lim inft→+∞ P{x(t) ≤
%} ≥ 1− ε for any ε ∈ (0, 1), which will be addressed step by step.
For the former, defining a Lyapunov function V 1(x) = 1/x1 (x1 > 0), and
then applying Itoˆ’s formula to the first equation of system (3.3) yields
dV 1(x1) = −V 1(x1)[r − rη
∏
0<nT<t(1− a(nT ))x1
−a∏0<nT<t(1 + b(nT ))y1]dt+ V 1(x1)δ21dt− V 1(x1)δ1dB1(t).
Choosing a positive constant ϑ which satisfies τ > 0.5ϑδ21, we then define
another Lyapunov function V 2(x1) = (1+V
1(x1))
ϑ, again Itoˆ’s formula leads
to
dV 2(x1) = ϑ(1 + V
1(x1))
ϑ−1dV 1(x1) + 0.5ϑ(ϑ− 1)(1 + V 1(x1))ϑ−2(dV 1(x1))2
= ϑ(1 + V 1(x1))
ϑ−2{−V 1(x1)− (V 1(x1))2[r − rη
∏
0<nT<t(1− a(nT ))x1
−a∏0<nT<t(1 + b(nT ))y1] + (V 1(x1) + (V 1(x1))2)δ21
+0.5(ϑ− 1)(V 1(x1))2δ21}dt− ϑ(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t)
= ϑ(1 + V 1(x1))
ϑ−2{−(V 1(x1))2[r − 0.5δ21 − 0.5ϑδ21
−a∏0<nT<t(1 + b(nT ))y1]
+V 1(x1)[−r + rη
∏
0<nT<t(1− a(nT ))
+a
∏
0<nT<t(1 + b(nT ))y1 + δ
2
1] + rη
∏
0<nT<t(1− a(nT ))}dt
−ϑ(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t)
≤ ϑ(1 + V 1(x1))ϑ−2{−(V 1(x1))2[τ − 0.5ϑδ21] + V 1(x1)[rηM1
+aM2 + δ
2
1] + rηM1}dt− ϑ(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t).
Further, we choose a sufficiently small ξ which satisfies
τ − 0.5ϑδ21 > ξϑ > 0. (4.12)
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And then define a Lyapunov function V 3(x1) = exp(ξt)V
2(x1), using Itoˆ’s
formula we have
dV 3(x1) = ξ exp(ξt)V
2(x1)dt+ exp(ξt)dV
2(x1)
≤ ϑ exp(ξt)(1 + V 1(x1))ϑ−2{ ξ(1+V 1(x1))2ϑ − (V 1(x1))2[τ − 0.5ϑδ21]
+V 1(x1)[rηM1 + aM2y0 + δ
2
1] + rηM1}dt
−ϑ exp(ξt)(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t).
= exp(ξt)f(x1)dt− ϑ exp(ξt)(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t),
where
f(x1) = ϑ(1 + V
1(x1))
ϑ−2{−[τ − 0.5ϑδ21 − ξϑ ](V 1(x1))2
+[rηM1 + aM2y0 + δ
2
1 +
2ξ
ϑ
]V 1(x1) + rηM1 +
ξ
ϑ
}.
Let C1 = τ − 0.5ϑδ21 − ξϑ , C2 = rηM1 + aM2 + δ21 + 2ξϑ and C3 = rηM1 + ξϑ ,
then C1 > 0, C2 > 0 and C3 > 0 because all parameters are positive and
(4.12) holds true. Thus, we can rewrite f(x1) as
f(x1) = ϑ(1 +
1
x1
)ϑ−2
{
−C1
x21
+
C2
x1
+ C3
}
.
= f1(x1).
Next we show that f(x1) is upper bounded when x1 > 0. If
1
x1
≥ C2+
√
C22+4C1C3
2C1
.
=
λ1, then f(x1) ≤ 0. If 0 < 1x1 ≤ λ1, then f1(x1) ≤
4C1C3+C22
4C1
. Furthermore, if
ϑ ≥ 2, then ϑ(1 + 1
x1
)ϑ−2 ≤ ϑ(1 + λ1)ϑ−2; if ϑ < 2, then ϑ(1 + 1x1 )ϑ−2 ≤ ϑ.
Therefore, for x1 > 0 we always have f(x1) ≤ f0 = λ2 4C1C3+C
2
2
4C1
, where
λ2 = max{ϑ, ϑ(1 + λ1)ϑ−2}. In other words, f(x1) is always upper bounded.
Moreover,
dV 3(x1) ≤ exp(ξt)f(x1)dt− ϑ exp(ξt)(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t)
≤ f0 exp(ξt)dt− ϑ exp(ξt)(1 + V 1(x1))ϑ−1V 1(x1)δ1dB1(t).
We integrate the above equation from 0 to t and thereafter take the expec-
tation, which yields
E[V 3(x1(t))] ≤ V 3(x1(0)) + f0
ξ
exp(ξt),
note that V 3(x1(t)) = exp(ξt)(1 + V
1(x1(t)))
ϑ, thus we obtain
E[V 3(x1(t))] = E[exp(ξt)(1 + V
1(x1(t)))
ϑ]
≤ V 3(x1(0)) + f0ξ exp(ξt)
= (1 + V 1(x1(0)))
ϑ + f0
ξ
exp(ξt).
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Taking the superior limit leads to
lim supt→+∞E[
1
x1(t)ϑ
] = lim supt→+∞E[(V
1(x1(t)))
ϑ]
≤ lim supt→+∞E[(1 + V 1(x1(t)))ϑ] ≤ f0ξ .
Due to x(t) =
∏
0<nT<t(1− a(nT ))x1(t), it is clear that
lim supt→+∞E[
1
x(t)ϑ
] = lim supt→+∞
1
[
∏
0<nT<t(1−a(nT ))]
ϑE[
1
x1(t)ϑ
] ≤ f0
mϑ1 ξ
.
= fM .
For arbitrary ε > 0, we denote β = ε
1
ϑ/f
1
ϑ
M . It follows from Chebyshev’s
inequality that one gets
lim supt→+∞ P{x(t) < β} = lim supt→+∞ P{ 1xϑ(t) > 1βϑ}
≤ lim supt→+∞
E[ 1
xϑ(t)
]
β−ϑ
= lim supt→+∞ β
ϑE[ 1
xϑ(t)
] = ε.
Therefore, lim inft→+∞ P{x(t) ≥ β} ≥ 1− ε.
For the latter, we also define a Lyapunov function V3(x1(t)) = x
p
1(t)
(x1 > 0), and the application of Itoˆ’s formula to the first equation of system
(3.3) yields
dV3(x1(t)) = pV3(x1(t))[r − rη
∏
0<nT<t(1− a(nT ))x1(t)
−a∏0<nT<t(1 + b(nT ))y1(t) + 0.5(p− 1)δ21]dt
+pδ1V3(x1(t))dB1(t)
≤ pV3(x1(t))[r − rηm1x1(t) + 0.5(p− 1)δ21]dt
+pδ1V3(x1(t))dB1(t),
integrating the above equation from 0 to t and then taking the expectation
yields
E[V3(x1(t))]−E[V3(x1(0))] ≤ p
∫ t
0
E{V3(x1(s))[r−rηm1x1(s)+0.5(p−1)δ21]}ds,
the derivative of the upper formula gives
dE[V3(x1(t))]
dt
≤ pE[V3(x1(t))][r + 0.5(p− 1)δ21]− prηm1E[xp+11 (t)].
According to Ho¨lder’s inequality we obtain
dE[V3(x1(t))]
dt
≤ pE[V3(x1(t))][r + 0.5(p− 1)δ21]− prηm1E[xp1(t)]
p+1
p .
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Let h(t) = E[V3(x1(t))] we obtain
dh(t)
dt
≤ ph(t)[r + 0.5(p− 1)δ21 − prηm1h
1
p (t)]
≤ ph(t)[r + 0.5pδ21 − prηm1h
1
p (t)].
Making using of the standard comparison theorem yields
lim supt→+∞E[x
p
1(t)] = lim supt→+∞E[V3(x1(t))]
= lim supt→+∞ h(t)
≤
(
r+0.5pδ21
prηm1
)p
.
Due to x(t) =
∏
0<nT<t(1− a(nT ))x1(t), thus
lim supt→+∞E[x
p(t)] = lim supt→+∞
(∏
0<nT<t(1− a(nT ))
)p
E[xp1(t)]
≤ Mp1
(
r+0.5pδ21
prηm1
)p
.
By using the same methods, it follows from Chebyshev’s inequality that
lim inf
t→+∞
P{x(t) ≤ %} ≥ 1− ε.
Therefore, based on the definitions the tumour cells are stochastically per-
manent. This completes the proof.
5. Numerical results
Since we have investigated the extinction and persistence for tumours, to
substantiate our results we carried out numerical simulations. In order to
show approximate solutions of system (2.2) with initial conditions, we use
the Milsteins higher order method [35], and then the discretization equations
of system (2.2) are xk+1 = xk + xk[r(1− ηxk)− ayk]∆t+ δ1xk
√
∆tξk +
δ21
2
xk(ξ
2
k − 1)∆t,
yk+1 = yk + yk
[
bxk
1+wxk
− cxk − d
]
∆t+ δ2yk
√
∆tηk +
δ22
2
yk(η
2
k − 1)∆t,
(5.13)
and at the impulsive point series nT system (2.2) experiences pulsed thera-
pies, i.e., if mod(k, T ) = 0, then we have{
xk+1 = (1− ak)xk,
yk+1 = (1 + bk)yk,
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where ξk and ηk(k = 1, 2, 3, ...) denote the independent Gaussian random
variables with distribution N(0, 1), we set time increment ∆t = 0.01.
The baseline parameter values of the stochastic system (2.2) without
pulses were chosen from the classical reference [10], because these values
were not only obtained by parameter estimation based on experimental data,
but also addressed the biological implications. Therefore, we fix η = 0.002,
a = 1, b = 1.131, w = 20.19, c = 0.00311 and d = 0.3. To be convincing the
logarithmic plots are carried out.
In Fig.1(a), we set r = 1.85, δ1 = 2, δ2 = 0.5, n = 100, T = 100, ak = 0.1
and bk = 0.05, the initial values were fixed as (x(0), y(0)) = (0.1, 0.5) and
(x(0), y(0)) = (10, 0.5). By calculation we have limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
≤
1
T
∑n
i=1 ln(1− a(iT )) + r − 12δ21 ≈ −0.149 < 0, in the light of Theorem 5 we
know that the tumours become extinct (Fig.1(a)). If we set r = 2.5 and fix
all other parameters as shown in Fig.1(a), it was found that
lim
t→+∞
sup
∑
0<nT<t ln(1− a(nT ))
t
+ r − 1
2
δ21 ≈ 0.5 > 0
and
lim
t→+∞
sup
∑
0<nT<t ln(1 + b(nT ))
t
− d− 1
2
δ22 ≈ −0.424 < 0,
by Theorem 5 we know that the tumours become weakly persistent in the
mean (Fig.1(b)).
In Fig. 2(a), we set r = 3, δ1 = 1, δ2 = 0.5, n = 100, T = 100, ak = 0.1
and bk = 0.05, the initial values were fixed as (x(0), y(0)) = (0.1, 0.5) and
(x(0), y(0)) = (10, 0.5), then τ = mint≥0[r − 12δ21 − aM2] ≈ 1.53 > 0. It
follows from Theorem 7 that the tumour cells are stochastically persistent
(Fig. 2(a)). When δ1 = 0, the amplitude becomes smaller (Fig. 2(b)). In this
case, periodical applications of immunotherapy could kill a certain amount of
tumours, but the immune action is not strong enough to control the cancer
cells and so they are in an unstable state.
In Fig.3(a), we set r = 1.85, δ1 = 2, δ2 = 0.5, n = 100, T = 100, ak = 0.1
and bk = 0.05, the initial values were fixed as (x(0), y(0)) = (10, 5). By
simple calculation we can show that
limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+ r − 1
2
δ21 ≈ −0.149 < 0,
limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− d+ 1
2
δ22 ≈ −0.424 < 0,
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then by Theorem 6 the effector cells become extinct. Moreover, if we set
bk = 0.6 and fix others parameter values as shown in Fig.3(a), then we have
limt→+∞ sup
∑
0<nT<t ln(1+b(nT ))
t
− (d+ 1
2
δ22
)
−
(
b−c
rη
limt→+∞ sup
∑
0<nT<t ln(1−a(nT ))
t
+
(
r − 1
2
δ21
)) ≈ 60.2 > 0,
by Theorem 6 the effector cells become weakly persistent in the mean (Fig.3(b)).
Under certain conditions, periodical applications of immunotherapy and
chemotherapy could clear a certain number of tumour cells but cannot com-
pletely remove the tumours from the body, so the strength of treatment needs
to be augmented in order to suppress the proliferation and mutation of tu-
mours. For example, a feasible strategy can be implemented by adjusting
the key parameters of the pulsed comprehensive therapy such as the dose of
immunotherapy and chemotherapy, the period of treatment and the number
of pulsed treatments. If we increase the dose of the chemotherapy, then the
tumours can be eradicated (Fig. 4(a) and Fig. 4(b)). Similarly, increasing
the dose of immunotherapy may also lead to the eradication of tumours and
we omit it. While decreasing the periodicity of pulsed treatment may also
control tumours (Fig. 4(c) and Fig. 4(d)).
6. Conclusions
It has been shown that the growth rate of tumours is inevitably affected by
environmental noise [18-21] and that periodical applications of immunother-
apy and chemotherapy are effective for treating tumours [9, 29, 30], with
the latter confirmed by experimental and clinical studies [22, 23]. In this
study, we have proposed a stochastic tumour-immune dynamical model with
pulsed comprehensive treatment to investigate how stochastic fluctuations
and combinations of immunotherapy with chemotherapy affect the evolution
of tumours.
First of all, the explicit expression of the tumour free solution is given
when tumour cells are eradicated, under certain conditions, and we show
that for system (2.2) there exists a global unique positive solution which
is globally attractive. Then the upper bound of the expectations of the
solutions was estimated. Biologically, if pulsed perturbations are bounded
or follow after finite pulse immunotherapy, then the tumour cells will be
controlled and will not grow indefinitely. By using Itoˆ’s formula and defining
Lyapunov functions, the sufficient conditions of extinction, non-persistece in
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the mean and weak persistence in the mean for the tumour cells and effector
cells were provided, and we also determine a condition for tumours being
stochastically permanent. From a biological view of point, when the doses
or frequencies of chemotherapy are large (i.e., the effect of chemotherapy
is significant), then large stochastic disturbances will lead to extinction of
tumours and small stochastic disturbances will result in weak persistence
in the mean of the tumours. If the stochastic disturbances are fixed as
being constant, then large doses or higher frequencies of chemotherapy will
lead to extinction of tumours and vice versa. Moreover, if the stochastic
disturbances are small or the initial density of effector cells is small or the
doses (or frequencies) of immunotherapy are small, then the tumours will
be stochastically permanent. Therefore, a feasible way to cure cancer is
either to increase doses or frequencies of chemotherapy, or to increase the
initial density of effector cells, or to augment the doses (or frequencies) of
immunotherapy.
One of the drawbacks of periodical applications of chemotherapy is the
emergence of drug resistance [36]. In the presence of drug resistance, it
is necessary to divide tumour cells into drug sensitive strains and drug re-
sistance strains [37], as alternate use of immunotherapy and chemotherapy
drugs may delay the onset of resistance. Future work is required to combine
pulsed treatment with a stochastic tumour-immune system to better prevent
the evolution of drug resistance.
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Figure Legends
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Figure 1: Extinction and weak persistence of tumours. (a) Time series of tumour cell
x(t) with r = 1.85; (b) Time series of tumour cells x(t) with r = 2.5. The initial values
of solution with black were fixed as (x(0), y(0)) = (0.1, 0.5) and red for (x(0), y(0)) =
(10, 0.5), and all other parameters were fixed as: η = 0.002, a = 1, b = 1.131, w = 20.19,
c = 0.00311, d = 0.3, δ1 = 2, δ2 = 0.5, n = 100, T = 100, a(nT ) = 0.1 and b(nT ) = 0.05.
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Figure 2: (a) Time series of tumour cells x(t) with δ1 = 1; (b) Time series of tumour cells
x(t) with δ1 = 0. The initial values of solution with black were fixed as (x(0), y(0)) =
(0.1, 0.5) and red for (x(0), y(0)) = (10, 0.5), and all other parameters were fixed as: r = 3,
η = 0.002, a = 1, b = 1.131, w = 20.19, c = 0.00311, d = 0.3, n = 100, δ2 = 0.5, T = 100,
a(nT ) = 0.1 and b(nT ) = 0.05.
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Figure 3: Extinction and weak persistence of effector cells. (a) Time series of effector cells
y(t) with b(nT ) = 0.05; (b) Time series of effector cells y(t) with b(nT ) = 0.6. The initial
values of solution were fixed as (x(0), y(0)) = (10, 5), and all other parameters were fixed
as: r = 1.85, η = 0.002, a = 1, b = 1.131, w = 20.19, c = 0.00311, d = 0.3, δ1 = 2,
δ2 = 0.5, n = 100, T = 100 and a(nT ) = 0.1.
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Figure 4: The effects of control parameters on the extinction of tumours. (a) Time series
of tumour cells x(t) with a(nT ) = 0.3 and T = 100; (b) Time series of tumour cells x(t)
with a(nT ) = 0.4 and T = 100; (c) Time series of tumour cells x(t) with a(nT ) = 0.1
and T = 40; (d) Time series of tumour cells x(t) with a(nT ) = 0.1 and T = 25. We set
initial values as (x(0), y(0)) = (0.1, 0.5) and all other parameters were fixed as: r = 2.5,
η = 0.002, a = 1, b = 1.131, w = 20.19, c = 0.00311, d = 0.3, δ1 = 2, δ2 = 0.5, n = 100
and b(nT ) = 0.05.
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